THIS REPORT:Provides a comprehensive overview of the global market for epigenomicsDescribes the major epigenomics technologies impacting the market today and emerging opportunities in biomarkers, diagnostics and therapeuticsContains global market forecasts for epigenomics, with trends and forecasts for growth through 2014Offers a focus on particular applications of epigenomics, including research tools, diagnostics, drugs and cloning/tissue engineeringDiscusses industry structure including, mergers and acquisitions, distribution of products, government regulation and industry trendsProfiles the most competitive businesses in the industry.
5 Cutting-Edge Trends in Molecular DiagnosticsBruce Carlson
Despite the focus on novelty in this field, it is near 2 decades old. Yet a lot is changing. A look at a few trends that could change molecular diagnostics.
Is insourcing NGS testing worth it?
Dartmouth-Hitchcock has experienced nearly 40% savings by bringing NGS testing in-house. A recent AMP study using non-small cell lung cancer as an example cites $2.7 million in anticipated savings.
In-house NGS testing is the foundation of any modern precision medicine program. It can have a profound effect on patient care. And, as these examples show, a strong business case can be made.
How have Dartmouth-Hitchcock and other progressive institutions been so successful despite myriad challenges?
Join us for a webinar on May 31st at 12pm ET as Eric Loo, MD (Dartmouth-Hitchcock) and Rakesh Nagarajan, MD, PhD (PierianDx) explore answers to this question and more.
In this webinar you will learn:
How recent precision medicine trends are driving strong market growth for clinical NGS and other complex molecular testing.
How to make a strong business case for in-house NGS testing.
Challenges your institution is likely to face by insourcing.
Blueprints for overcoming these challenges, including reimbursement.
Cancer Diagnostics Reference Laboratory / NeoGenomics April 2014 investors company overview presentation. This presentation highlights the following:
--Fast growing cancer genetics lab servicing Oncologists, Pathologists and Hostpitals
--Strategic client partnerships created by "Tech-Only" model
--Dynamic, rapidly-growing and consolidating industry
Industry-leading revenue & test volume growth
--Strong productivity and operating leverage leading to accelerating cash flow and net income
--Strong Management Team with large cap lab experience
There will be a steady increase in demand for new diagnostic testing services in the next five-year period, along with pressures to improve the quality of healthcare delivered in the clinic and also to lower its costs. Clinical labs experienced a substantial growth during the last decade. The emphasis in this TriMark Publications report is on those companies that are actively developing and marketing high-growth diagnostic testing technologies in the clinical hospital market. It defines the dollar volume of sales, both worldwide and in the U.S., of the market and analyzes the factors that influence the size and growth of market segments. The study goes on to discuss in detail trends that have developed which have stimulated this market, and also comments in detail patterns of information processing in the high-growth diagnostic testing technologies. Moreover, this exanimation provides an overview of the diagnostic testing market, including the latest information regarding exciting new products and industry trends. It will not only quantify but also qualify the market high-growth segments as an area of research and investment. Forecasts of the market and analyses of products in the worldwide prescriptions market will provide a basis for understanding the significance of past developments and future possibilities within this therapeutic category.
Global Psoriasis Pipeline Drugs Market Assessment – Forecast to 2023AzothAnalytics
A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of Global Psoriasis Pipeline Drugs Market by assessing the potential of the six drugs that will be launched in the near future. Also, the report assesses the results of various clinical trials undertaken for each of the six drugs, the product profile, description and regulatory phase of each of the six drugs. Also, 7Ps Analysis (Patent, Phase, Pathway, Patient, Physician, Payer, Partner) has been done for each of the six drugs to present the current perspective.
Next Generation Sequencing Market, By Types of Test, Companies, ForecastNehaSingh522734
Next Generation Sequencing Market will reach US$ 34.8 Billion by 2027. Global Forecast, Impact of COVID-19, Industry Trends, Growth, Opportunity By Types of Test, Company Analysis.
Future Horizons in the European Molecular Diagnostics Market--France, Germany...ReportLinker.com
This comprehensive five-country report is designed to help current suppliers and potential market entrants identify and evaluate major business opportunities emerging in the molecular diagnostics market during the next five years. The report explores business and technological trends in major European countries (France, Germany, Italy, Spain, UK); provides 5-year test volume/sales forecasts; estimates shares of leading competitors; compares features of major analyzers; profiles leading market players; and identifies specific product and business opportunities facing instrument and consumable suppliers during the next five years.The $4.5 billion molecular diagnostics market is unquestionably the most rapidly growing segment of the in vitro diagnostics industry. The next five years will witness significant developments in reagent systems and automation, as well as introduction of a wide range of new products that will require innovative marketing approaches. The rate of market penetration into routine clinical laboratories, however, will depend on the introduction of cost-effective and automated systems with amplification methods. In order to successfully capitalize on the opportunities presented by the molecular diagnostics market, many companies are already exploiting new technologies as corporate strategic assets, managed in support of business and marketing strategies. Integrating new technology planning with business and corporate strategies will be one of the most challenging tasks for diagnostics companies during the next five years. Contains 970 pages and 75 tables
Innovative Molecular Diagnostic Technologies and Emerging MarketsReportLinker.com
This unique seven-country report contains 1,050 pages, 96 tables, and is designed to help current suppliers and potential market entrants identify and evaluate major business opportunities emerging in the molecular diagnostics market during this decade. The report explores business and technological trends in the US, five major European countries, (France, Germany, Italy, Spain, UK) and Japan; provides 5- and 10-year test volume/sales forecasts; estimates shares of leading competitors; compares features of major analyzers; profiles leading market players; and identifies specific product and business opportunities facing instrument and consumable suppliers during the next ten years.The molecular diagnostics market is unquestionably the most rapidly growing segment of the in vitro diagnostics industry. The next ten years will witness significant developments in reagent systems and automation, as well as introduction of a wide range of new products that will require innovative marketing approaches. The rate of market penetration into routine clinical laboratories, however, will depend on the introduction of cost-effective and automated systems with amplification methods. In order to successfully capitalize on the opportunities presented by the molecular diagnostics market, many companies are already exploiting new DNA probe and biochip technologies as corporate strategic assets, managed in support of business and marketing strategies. Integrating new technology planning with business and corporate strategies will be one of the most challenging tasks for diagnostics companies during the next ten years.
5 Cutting-Edge Trends in Molecular DiagnosticsBruce Carlson
Despite the focus on novelty in this field, it is near 2 decades old. Yet a lot is changing. A look at a few trends that could change molecular diagnostics.
Is insourcing NGS testing worth it?
Dartmouth-Hitchcock has experienced nearly 40% savings by bringing NGS testing in-house. A recent AMP study using non-small cell lung cancer as an example cites $2.7 million in anticipated savings.
In-house NGS testing is the foundation of any modern precision medicine program. It can have a profound effect on patient care. And, as these examples show, a strong business case can be made.
How have Dartmouth-Hitchcock and other progressive institutions been so successful despite myriad challenges?
Join us for a webinar on May 31st at 12pm ET as Eric Loo, MD (Dartmouth-Hitchcock) and Rakesh Nagarajan, MD, PhD (PierianDx) explore answers to this question and more.
In this webinar you will learn:
How recent precision medicine trends are driving strong market growth for clinical NGS and other complex molecular testing.
How to make a strong business case for in-house NGS testing.
Challenges your institution is likely to face by insourcing.
Blueprints for overcoming these challenges, including reimbursement.
Cancer Diagnostics Reference Laboratory / NeoGenomics April 2014 investors company overview presentation. This presentation highlights the following:
--Fast growing cancer genetics lab servicing Oncologists, Pathologists and Hostpitals
--Strategic client partnerships created by "Tech-Only" model
--Dynamic, rapidly-growing and consolidating industry
Industry-leading revenue & test volume growth
--Strong productivity and operating leverage leading to accelerating cash flow and net income
--Strong Management Team with large cap lab experience
There will be a steady increase in demand for new diagnostic testing services in the next five-year period, along with pressures to improve the quality of healthcare delivered in the clinic and also to lower its costs. Clinical labs experienced a substantial growth during the last decade. The emphasis in this TriMark Publications report is on those companies that are actively developing and marketing high-growth diagnostic testing technologies in the clinical hospital market. It defines the dollar volume of sales, both worldwide and in the U.S., of the market and analyzes the factors that influence the size and growth of market segments. The study goes on to discuss in detail trends that have developed which have stimulated this market, and also comments in detail patterns of information processing in the high-growth diagnostic testing technologies. Moreover, this exanimation provides an overview of the diagnostic testing market, including the latest information regarding exciting new products and industry trends. It will not only quantify but also qualify the market high-growth segments as an area of research and investment. Forecasts of the market and analyses of products in the worldwide prescriptions market will provide a basis for understanding the significance of past developments and future possibilities within this therapeutic category.
Global Psoriasis Pipeline Drugs Market Assessment – Forecast to 2023AzothAnalytics
A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of Global Psoriasis Pipeline Drugs Market by assessing the potential of the six drugs that will be launched in the near future. Also, the report assesses the results of various clinical trials undertaken for each of the six drugs, the product profile, description and regulatory phase of each of the six drugs. Also, 7Ps Analysis (Patent, Phase, Pathway, Patient, Physician, Payer, Partner) has been done for each of the six drugs to present the current perspective.
Next Generation Sequencing Market, By Types of Test, Companies, ForecastNehaSingh522734
Next Generation Sequencing Market will reach US$ 34.8 Billion by 2027. Global Forecast, Impact of COVID-19, Industry Trends, Growth, Opportunity By Types of Test, Company Analysis.
Future Horizons in the European Molecular Diagnostics Market--France, Germany...ReportLinker.com
This comprehensive five-country report is designed to help current suppliers and potential market entrants identify and evaluate major business opportunities emerging in the molecular diagnostics market during the next five years. The report explores business and technological trends in major European countries (France, Germany, Italy, Spain, UK); provides 5-year test volume/sales forecasts; estimates shares of leading competitors; compares features of major analyzers; profiles leading market players; and identifies specific product and business opportunities facing instrument and consumable suppliers during the next five years.The $4.5 billion molecular diagnostics market is unquestionably the most rapidly growing segment of the in vitro diagnostics industry. The next five years will witness significant developments in reagent systems and automation, as well as introduction of a wide range of new products that will require innovative marketing approaches. The rate of market penetration into routine clinical laboratories, however, will depend on the introduction of cost-effective and automated systems with amplification methods. In order to successfully capitalize on the opportunities presented by the molecular diagnostics market, many companies are already exploiting new technologies as corporate strategic assets, managed in support of business and marketing strategies. Integrating new technology planning with business and corporate strategies will be one of the most challenging tasks for diagnostics companies during the next five years. Contains 970 pages and 75 tables
Innovative Molecular Diagnostic Technologies and Emerging MarketsReportLinker.com
This unique seven-country report contains 1,050 pages, 96 tables, and is designed to help current suppliers and potential market entrants identify and evaluate major business opportunities emerging in the molecular diagnostics market during this decade. The report explores business and technological trends in the US, five major European countries, (France, Germany, Italy, Spain, UK) and Japan; provides 5- and 10-year test volume/sales forecasts; estimates shares of leading competitors; compares features of major analyzers; profiles leading market players; and identifies specific product and business opportunities facing instrument and consumable suppliers during the next ten years.The molecular diagnostics market is unquestionably the most rapidly growing segment of the in vitro diagnostics industry. The next ten years will witness significant developments in reagent systems and automation, as well as introduction of a wide range of new products that will require innovative marketing approaches. The rate of market penetration into routine clinical laboratories, however, will depend on the introduction of cost-effective and automated systems with amplification methods. In order to successfully capitalize on the opportunities presented by the molecular diagnostics market, many companies are already exploiting new DNA probe and biochip technologies as corporate strategic assets, managed in support of business and marketing strategies. Integrating new technology planning with business and corporate strategies will be one of the most challenging tasks for diagnostics companies during the next ten years.
Rakesh Nagarajan, MD, PhD and founder of PierianDx, discusses the rise of precision medicine programs and makes the business case for healthcare institutions to build their own clinical NGS testing programs.
TransCode Therapeutics Inc is an RNA oncology company. It is created to defeat the cancer through the intelligent design and effective delivery of RNA therapeutics. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which has the potential to produce regression without recurrence in a range of cancers, including breast, pancreatic, ovarian and colon cancer, glioblastomas and others.
“Next-Generation Sequencing (NGS) Global Market – Forecast To 2022”Vinay Shiva Prasad
Next Generation Sequencing (NGS) has revolutionized the way the human genomes are being sequenced now a days. The time and cost to sequence has tremendously reduced . In the last five years, the sequencing cost has rapidly reduced and this is supposed to have a huge impact on the NGS market in the coming years.
Optimizing the Output of Your Molecular Pathology LaboratoryJosh Forsythe
If you are a clinical lab looking to build or accelerate your NGS testing capability where do you start? The components of success can be overwhelming - planning, assay design, validation, clinical lab workflow, informatics, and interpretation.
During this one-hour webinar, BG Jones, SVP of Business Development for PierianDx, who has 23 years of experience in healthcare IT and genomics technology, will demonstrate how to pull it all together using "Actionable Intelligence" - a combination of machine learning and human expertise to achieve clinically actionable insights.
Dr. Michael S. Perry - Afternoon Keynote Presentationmarsinnovation
Afternoon Keynote Presentation
Dr. Michael S. Perry, Venture Partner, Bay City Capital; President and Chief Medical Officer, Poniard Pharmaceuticals (US)
MaRS Innovation Summit
October 28, 2010
Global next generation sequencing market size, share & forecast, 2025TechSci Research
According to www.techsciresearch.com latest Report- Global next-generation sequencing market is projected to grow at a CAGR of close to 20% to reach USD24 billion during the forecast period. Enhancing regulatory framework for next-generation sequencing based tests for diagnostics is the key factor for the growth of global next-generation sequencing market during the forecast period.
Report URL- https://www.techsciresearch.com/report/next-generation-sequencing-market/4508.html
Regenerative Medicines: Bone and Joint ApplicationsReportLinker.com
Provides a comprehensive overview of the global market for regenerative medicines for bone and joint applicationsOffers the background for demographics underlying the market for bone and joint productsContains global market forecasts for regenerative medicines for bone and joint applications, with trends and forecasts for growth through 2014Describes the leading bone and joint diseases and disorders using regenerative technologies, including incidence and current methods of treatmentDiscusses regulatory issues affecting regenerative medicine productsProfiles leading and emerging companies.
This report analyzes the worldwide markets for Molecular Diagnostics in US$ million by the following segments: Infectious Disease Testing, Pharmacogenomics, and Cancer Screening. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2007 through 2015. A seven-year historic analysis is also provided for these markets. The report profiles 101 companies including many key and niche players such as Abbott Laboratories, Abbott Molecular, Applera Corporation, Celera, Biom
Global Sterilization Systems & Equipment IndustryReportLinker.com
This report analyzes the worldwide markets for Sterilization Systems & Equipment in US$ Million by the following segments: Steam/Autoclave, Ethylene Oxide, Gas Plasma, Gamma Radiation, E-Beam Radiation, Other Methods, and Sterilization Supplies. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East & Africa, and Latin America. Annual estimates and forecasts are provided for the period 2007 through 2015. A seven-year historic analysis is also provided for these markets. The report profiles 143 companies including many key and niche players such as 3M Company, Advanced Sterilization Products, Cantel Medical Corp, Minntech Corporation, Getinge AB, L3 Pulse Sciences, SteriGenics International, Inc., STERIS Corporation, TSO3, and Tuttnauer Company. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.
Global Cardiovascular Disease Diagnostics IndustryReportLinker.com
This report analyzes the worldwide markets for Cardiovascular Disease Diagnostics in US$ Million by the following product segments - Annual estimates and forecasts are provided for the period 2007 through 2015. Also, a seven-year historic analysis is provided for these markets. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia Pacific, Middle East, and Latin America. The report profiles 71 companies including many key and niche players worldwide such as AccuTech, LLC, Abbott Diagnostics, Alere Inc., Biosite, Inc., Ani Biotech Oy, Axis-Shield PoC, Beckman Coulter, Inc., biom
Gastrointestinal Pharmaceuticals: Technologies and MarketsReportLinker.com
Overall sales in the gastrointestinal disorder treatment market amounted to $34.2 billionin 2007, and decreased slightly to $31.1 billion in 2009. By 2014, they are projected to reach $32.2 billion, for a 5-year compound annual growth rate (CAGR) of 0.7%.The largest segment of the market, prescription gastrointestinal drugs, was valued at $27.4 billion in 2008; this is expected to decrease to $26,3 billion in 2009, and to reach $27 billion in 2014, for a 5-year CAGR of 0.5%.
Genome Editing Market Analysis By Technology (CRISPR, TALEN, ZFN), By Delivery Method (Ex-vivo, In-vivo), By Application (Animal/Plant Cell Editing), By Service (In-house, Outsourced), By End-use And Segment Forecasts, 2018 - 2025
Global Molecular Diagnostics Market: Innovative Technologies and Emerging Bus...ReportLinker.com
This unique seven-country report contains 1,050 pages, 96 tables, and is designed to help current suppliers and potential market entrants identify and evaluate major business opportunities emerging in the molecular diagnostics market during this decade. The report explores business and technological trends in the US, five major European countries, (France, Germany, Italy, Spain, UK) and Japan; provides 5- and 10-year test volume/sales forecasts; estimates shares of leading competitors; compares features of major analyzers; profiles leading market players; and identifies specific product and business opportunities facing instrument and consumable suppliers during the next ten years.The molecular diagnostics market is unquestionably the most rapidly growing segment of the in vitro diagnostics industry. The next ten years will witness significant developments in reagent systems and automation, as well as introduction of a wide range of new products that will require innovative marketing approaches. The rate of market penetration into routine clinical laboratories, however, will depend on the introduction of cost-effective and automated systems with amplification methods. In order to successfully capitalize on the opportunities presented by the molecular diagnostics market, many companies are already exploiting new DNA probe and biochip technologies as corporate strategic assets, managed in support of business and marketing strategies. Integrating new technology planning with business and corporate strategies will be one of the most challenging tasks for diagnostics companies during the next ten years.
Regenerative medicine is a way of treating injured and diseased human tissue by using laboratory-grown or therapeutically-induced human tissue as a replacement. As such, astounding new advancements in the ability to repair or replace damaged human tissue and organ functions are being made. Whereas before, remedies for damaged tissue or organ functions due to congenital deformities, injuries, diseases or simple wear-and-tear relied upon either the body's ability to repair itself (or not), or a surgeon's skilled hands. Now, the area of regenerative medicine promises to revolutionize humanity's ability to remediate countless physical maladies that have perpetually afflicted humans and other animals. Compared to a select few life forms--like the starfish--man-made solutions for tissue repair and organ replacement haven't come close to nature's solutions. And where there once was no solution even offered by nature, researchers are now at the cusp of overcoming such limitations by literally regrowing damaged tissue and restoring organ functions through the use of tissue engineering and stem cell therapy. This is the promise of regenerative medicine. This TriMark Publications report discusses the current state of regenerative medicine. The study provides a thorough overview of regenerative medicine sector together with analyses of the funding trends, intellectual property, market opportunities, therapeutic pipeline, research collaborations, partnership activities, and guidelines for establishing new ventures. The report enables the reader gain in-depth knowledge about ongoing tissue engineering and stem cell therapy research programs carried out in universities and other research centers. Moreover, this analysis profiles the leading companies developing regenerative medicine solutions.
Rakesh Nagarajan, MD, PhD and founder of PierianDx, discusses the rise of precision medicine programs and makes the business case for healthcare institutions to build their own clinical NGS testing programs.
TransCode Therapeutics Inc is an RNA oncology company. It is created to defeat the cancer through the intelligent design and effective delivery of RNA therapeutics. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which has the potential to produce regression without recurrence in a range of cancers, including breast, pancreatic, ovarian and colon cancer, glioblastomas and others.
“Next-Generation Sequencing (NGS) Global Market – Forecast To 2022”Vinay Shiva Prasad
Next Generation Sequencing (NGS) has revolutionized the way the human genomes are being sequenced now a days. The time and cost to sequence has tremendously reduced . In the last five years, the sequencing cost has rapidly reduced and this is supposed to have a huge impact on the NGS market in the coming years.
Optimizing the Output of Your Molecular Pathology LaboratoryJosh Forsythe
If you are a clinical lab looking to build or accelerate your NGS testing capability where do you start? The components of success can be overwhelming - planning, assay design, validation, clinical lab workflow, informatics, and interpretation.
During this one-hour webinar, BG Jones, SVP of Business Development for PierianDx, who has 23 years of experience in healthcare IT and genomics technology, will demonstrate how to pull it all together using "Actionable Intelligence" - a combination of machine learning and human expertise to achieve clinically actionable insights.
Dr. Michael S. Perry - Afternoon Keynote Presentationmarsinnovation
Afternoon Keynote Presentation
Dr. Michael S. Perry, Venture Partner, Bay City Capital; President and Chief Medical Officer, Poniard Pharmaceuticals (US)
MaRS Innovation Summit
October 28, 2010
Global next generation sequencing market size, share & forecast, 2025TechSci Research
According to www.techsciresearch.com latest Report- Global next-generation sequencing market is projected to grow at a CAGR of close to 20% to reach USD24 billion during the forecast period. Enhancing regulatory framework for next-generation sequencing based tests for diagnostics is the key factor for the growth of global next-generation sequencing market during the forecast period.
Report URL- https://www.techsciresearch.com/report/next-generation-sequencing-market/4508.html
Regenerative Medicines: Bone and Joint ApplicationsReportLinker.com
Provides a comprehensive overview of the global market for regenerative medicines for bone and joint applicationsOffers the background for demographics underlying the market for bone and joint productsContains global market forecasts for regenerative medicines for bone and joint applications, with trends and forecasts for growth through 2014Describes the leading bone and joint diseases and disorders using regenerative technologies, including incidence and current methods of treatmentDiscusses regulatory issues affecting regenerative medicine productsProfiles leading and emerging companies.
This report analyzes the worldwide markets for Molecular Diagnostics in US$ million by the following segments: Infectious Disease Testing, Pharmacogenomics, and Cancer Screening. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2007 through 2015. A seven-year historic analysis is also provided for these markets. The report profiles 101 companies including many key and niche players such as Abbott Laboratories, Abbott Molecular, Applera Corporation, Celera, Biom
Global Sterilization Systems & Equipment IndustryReportLinker.com
This report analyzes the worldwide markets for Sterilization Systems & Equipment in US$ Million by the following segments: Steam/Autoclave, Ethylene Oxide, Gas Plasma, Gamma Radiation, E-Beam Radiation, Other Methods, and Sterilization Supplies. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East & Africa, and Latin America. Annual estimates and forecasts are provided for the period 2007 through 2015. A seven-year historic analysis is also provided for these markets. The report profiles 143 companies including many key and niche players such as 3M Company, Advanced Sterilization Products, Cantel Medical Corp, Minntech Corporation, Getinge AB, L3 Pulse Sciences, SteriGenics International, Inc., STERIS Corporation, TSO3, and Tuttnauer Company. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.
Global Cardiovascular Disease Diagnostics IndustryReportLinker.com
This report analyzes the worldwide markets for Cardiovascular Disease Diagnostics in US$ Million by the following product segments - Annual estimates and forecasts are provided for the period 2007 through 2015. Also, a seven-year historic analysis is provided for these markets. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia Pacific, Middle East, and Latin America. The report profiles 71 companies including many key and niche players worldwide such as AccuTech, LLC, Abbott Diagnostics, Alere Inc., Biosite, Inc., Ani Biotech Oy, Axis-Shield PoC, Beckman Coulter, Inc., biom
Gastrointestinal Pharmaceuticals: Technologies and MarketsReportLinker.com
Overall sales in the gastrointestinal disorder treatment market amounted to $34.2 billionin 2007, and decreased slightly to $31.1 billion in 2009. By 2014, they are projected to reach $32.2 billion, for a 5-year compound annual growth rate (CAGR) of 0.7%.The largest segment of the market, prescription gastrointestinal drugs, was valued at $27.4 billion in 2008; this is expected to decrease to $26,3 billion in 2009, and to reach $27 billion in 2014, for a 5-year CAGR of 0.5%.
Genome Editing Market Analysis By Technology (CRISPR, TALEN, ZFN), By Delivery Method (Ex-vivo, In-vivo), By Application (Animal/Plant Cell Editing), By Service (In-house, Outsourced), By End-use And Segment Forecasts, 2018 - 2025
Global Molecular Diagnostics Market: Innovative Technologies and Emerging Bus...ReportLinker.com
This unique seven-country report contains 1,050 pages, 96 tables, and is designed to help current suppliers and potential market entrants identify and evaluate major business opportunities emerging in the molecular diagnostics market during this decade. The report explores business and technological trends in the US, five major European countries, (France, Germany, Italy, Spain, UK) and Japan; provides 5- and 10-year test volume/sales forecasts; estimates shares of leading competitors; compares features of major analyzers; profiles leading market players; and identifies specific product and business opportunities facing instrument and consumable suppliers during the next ten years.The molecular diagnostics market is unquestionably the most rapidly growing segment of the in vitro diagnostics industry. The next ten years will witness significant developments in reagent systems and automation, as well as introduction of a wide range of new products that will require innovative marketing approaches. The rate of market penetration into routine clinical laboratories, however, will depend on the introduction of cost-effective and automated systems with amplification methods. In order to successfully capitalize on the opportunities presented by the molecular diagnostics market, many companies are already exploiting new DNA probe and biochip technologies as corporate strategic assets, managed in support of business and marketing strategies. Integrating new technology planning with business and corporate strategies will be one of the most challenging tasks for diagnostics companies during the next ten years.
Regenerative medicine is a way of treating injured and diseased human tissue by using laboratory-grown or therapeutically-induced human tissue as a replacement. As such, astounding new advancements in the ability to repair or replace damaged human tissue and organ functions are being made. Whereas before, remedies for damaged tissue or organ functions due to congenital deformities, injuries, diseases or simple wear-and-tear relied upon either the body's ability to repair itself (or not), or a surgeon's skilled hands. Now, the area of regenerative medicine promises to revolutionize humanity's ability to remediate countless physical maladies that have perpetually afflicted humans and other animals. Compared to a select few life forms--like the starfish--man-made solutions for tissue repair and organ replacement haven't come close to nature's solutions. And where there once was no solution even offered by nature, researchers are now at the cusp of overcoming such limitations by literally regrowing damaged tissue and restoring organ functions through the use of tissue engineering and stem cell therapy. This is the promise of regenerative medicine. This TriMark Publications report discusses the current state of regenerative medicine. The study provides a thorough overview of regenerative medicine sector together with analyses of the funding trends, intellectual property, market opportunities, therapeutic pipeline, research collaborations, partnership activities, and guidelines for establishing new ventures. The report enables the reader gain in-depth knowledge about ongoing tissue engineering and stem cell therapy research programs carried out in universities and other research centers. Moreover, this analysis profiles the leading companies developing regenerative medicine solutions.
Multiplex Assays in Translational Medicine: Technologies, Applications, and F...ReportLinker.com
The development and growth of assay technologies has pushed translational medicine into a category unto itself. In a broad perspective on this field, this new report:Defines translational medicine by giving some historical background as well as providing personal definitions from experts in the field Discusses the evolution of assay technologies Reviews currently available assay technologies that apply directly to translational medicine Describes and evaluates current applications of these technologies Provides case studies of clinicians currently using this technology in their research Discusses future directions of assay technologies for translational medicine Gives input from the FDA on translation medicine and assay technologies Provides interviews from experts in the field of both translational medicine and specific assay technologies Profiles premier companies active in the field Assay technologies have been evolving since scientists first discovered they could measure glucose, insulin, and several hormones in the blood to help them diagnose disease. Early instruments such as the Ames Reflectance Meter, used for detecting glucose levels, have morphed into such sophisticated systems as flow cytometers. The Human Genome Project provided the basics for researchers to launch into the field of human genomics and they needed the tools to accomplish this. DNA microarrays allowed for massively parallel gene expression analyses. Scientists soon discovered that while the genomewide assays were extremely valuable, there were genes of interest that they had difficulty measuring when they got hundreds of data points from a microarray. Low- to mid-density assays have allowed scientists to pinpoint the genetic code for a variety of uses, from genetic heredity studies to drug metabolism and patient stratification.
Minimally invasive medical robotics, imaging & visualization systems & surgic...Ron Ethell
The MIS market is expected to grow at a fast rate with a CAGR of 8.2% and is expected to reach $35.5 billion by 2016. The surgical instruments segment commanded the larger share; i.e. 38.4%, of the global minimally invasive surgical devices market in 2011. This growth has been primarily attributed to the increased usage of these devices and instruments in MIS procedures. Devices such as guiding catheters and guidewires as well as balloons have been widely used in interventional angioplasty and peripheral extremity MIS procedures. Numerous innovations in the technologies of devices such as balloons have added to the growth in the market.
INTRODUCTIONSTUDY GOALS AND OBJECTIVESBCC's goal in conducting this study was to understand the current status of the U.S. dermatological therapeutics industry and to assess it in the medium term from 2008 through 2013. We were particularly interested in understanding the future market potential for the current and emerging technologies and products within the dermatological therapeutics industry. This report assesses the available therapeutic procedures for skin, along with the drugs and technologies currently being used for various skin treatments. The role of public agencies, the regulatory environment, and non-governmental stakeholders has also been examined.REASONS FOR DOING THIS STUDYSkin disorders have a high active as well as passive morbidity in most human populations across the world. Yet, most dermatology manufacturers and dermatologists rely on cosmetic applications and procedures for survival.INTENDED AUDIENCEThis study is likely to be of interest to individuals and organizations involved in aspects of dermatological therapeutics industry, such as research, manufacturing and even large buyers in the industry. This report will also be of interest to manufacturers and marketers of dermatological therapeutics industry across the world.
Download Global cancer nanomedicine market outlook 2022KuicK Research
“Global Cancer Nanomedicine Market Outlook 2022” Report Highlights:
Overview and Mechanism of Action of Nanomedicine
Nanomedicine Engineering: Design and Strategy
Cancer Nanomedicine as Diagnostic and Therapeutics Tool
Global Cancer Nanomedicine Market Overview and Dynamics
Global Cancer Nanomedicine Clinical Pipeline by Company, Indication and Phase
Global Cancer Nanomedicine Clinical Pipeline: 124 Drug
Marketed Cancer Nanomedicine: 8 Drugs
Global cancer nanomedicine market outlook 2022Rajesh Sarma
“Global Cancer Nanomedicine Market Outlook 2022” Report Highlights:
Overview & Mechanism of Action of Nanomedicine
Nanomedicine Engineering: Design & Strategy
Cancer Nanomedicine as Diagnostic & Therapeutics Tool
Global Cancer Nanomedicine Market Overview & Dynamics
Global Cancer Nanomedicine Clinical Pipeline by Company, Indication & Phase
Global Cancer Nanomedicine Clinical Pipeline: 124 Drug
Marketed Cancer Nanomedicine: 8 Drugs
The 2011 Clinical Chemistry and Immunodiagnostics Markets: US, Europe, Japan&...ReportLinker.com
During the next decade, the clinical chemistry and immunodiagnostics markets will undergo significant transformation. The changes will be caused convergence of new and more stringent regulations; advances in diagnostic technologies, system engineering, automation, and IT; and intensifying competition. Some segments, like routine chemistry, will resemble commodity markets, where product positioning and cost per test are more critical than underlying technology. This evolving marketplace will create exciting opportunities for a variety of new instruments, reagent systems, and auxiliary products, such as specimen preparation devices, controls, calibrators and others."The Clinical Chemistry and Immunodiagnostics Markets" is a unique worldwide market intelligence and technology assessment study designed to help current suppliers and potential market entrants identify and evaluate emerging opportunities and develop effective strategic responses. The study explores future trends in the U.S., five major European countries and Japan; provides estimates of the specimen, test and sales volumes, as well as major suppliers' sales and market shares; compares features of leading analyzers; profiles key competitors; and identifies specific product and marketing opportunities facing suppliers during the next ten years.Contains 1,115 pages and 450 tables
The U.S. medical plastics market is expected to reach almost 3.5 billion pounds by the end of 2010 and will grow at a compound annual growth rate (CAGR) of about 5%, consuming about 4.4 billion pounds by 2015.Commodity thermoplastics dominate the market with a little more than 55% of total volume. This sector is estimated at nearly 2 billion pounds in 2010 and should increase at a compound annual growth rate (CAGR) of 4.8% to reach 2.5 billion pounds in 2015.TPEs, engineering resins, and thermosets will show the most significant growth rates over the next 5 years although they only constitute about 20% of total volume. Of these, TPEs will experience the highest compound annual growth rate (CAGR) of 6.2%, from 68 million pounds in 2010 to 92 million pounds in 2015.
Smartphones: When is the first and last time you check yours?ReportLinker.com
Nearly half (46%) of Americans say they check their smartphones as soon as they wake up, while they’re still in bed, according to ReportLinker’s survey results. This is especially true of Millennials, 66% of whom say it’s the first thing they do before getting out of bed.
75% of Ameircans say they keep their smartphones active all day and night, and a staggering 83% of Millennials say they do.
In fact, disconnecting can be hard. More than half of Americans say their last check is right before bed – and 13% say they disconnect only after they’ve gotten into bed for the night. Even after they fall asleep, about 10% say they’ll wake up and check it during the night.
This graphic shows Samsung's customers are still loyal: 86% of Samsung Customers would consider Samsung next time they upgrade their smartphone. More info on reportlinker.com/inisght
Allegra Strategies is proud to release the 2012 report on European branded coffee shop market, providing comprehensive research on this fast developing market.The ProjectCaf
Allegra's definitive annual study on the UK branded coffee shop market is now available; with insight from over 25,000 consumers the report provides an authoritative view of the market.Drawing on more than 12 years in-depth research, it is considered to be the bible of the coffee sector.KEY AREAS COVERED' Market size and growth projections for the total UK market' Impact of recent economic downturn on trading performance' Key player profiles, including financial performance, pricing analysis and forecasts' Importance of ethical and sustainability issues' Key success factors and market trends' Opportunities and challenges for suppliers' Consumer coffee consumption patterns' Consumer brand awareness and perceptions of key players' Differences between customer demographics, including age, gender, occupation and location by the reportSOURCE OF INFORMATION' Interviews with CEOs, managing directors, senior managers and store managers of major industry players, including:' leading UK coffee and food-focused chains' major coffee roasters and key equipment suppliers' non-specialist players including department stores, supermarkets, bookstores' leading property companies, letting agents and landlords' local authorities' Online surveys with UK coffee shop visitors' Desk research including: News articles and trade press, the Internet and company websites,industry associations, published accounts, data supplied by operators' In-store observations and analysis
Wireless Infrastructure: Market Shares, Strategies, and Forecasts, Worldwide,...ReportLinker.com
WinterGreen Research announces that it has published a new study Wireless Infrastructure: Market Shares, Strategy, and Forecasts, Worldwide, 2013 to 2019. Next generation mission critical systems are leveraging new technology. The 2013 study has 554 pages, 245 tables and figures. Worldwide Wireless Infrastructure markets are poised to achieve significant growth as Building out core networks and backhaul for smart phones.A smart phone is not very smart if the infrastructure can't support its applications. In response to the high growth smart phone markets, wireless infrastructure promises to grow dramatically in the near term.. Wireless Infrastructure technologies include WiMax, LTE, 4G and HSPA. These technologies are driving much higher capacity from the base station back to the fiber core. Fiber core is putting extreme pressure on provider's infrastructure and backhaul networks.WinterGreen Research predicts that the dramatic growth of wireless infrastructure is based on the growth of smart phones to a one trillion market by 2019, serving an installed base of 8.5 billion, many people having more than one smart phone. Wireless infrastructure markets at $58 billion in 2012 will be $163 billion by 2019, new markets evolved because of the value that apps provide to smart phones, mobile devices, tablets, and the Internet of things.According to Susan Eustis, lead author of the study, 'Wireless Infrastructure is being installed to upgrade core networks and upgrade backhaul and base stations to make systems more modern. Infrastructure for the Internet and for smart mobile devices creates demand for more sophisticated web development and web applications that in turn depend on more sophisticated infrastructure. Everything is going mobile. This evolution is driven by mobile smart phones and tablets that provide universal connectivity. Modern systems represent a significant aspect of Internet market evolution.'The proportions of wireless infrastructure market industry segments are expected to remain much as they are, with the small cells and femtocells achieving strong growth on the access side, the core infrastructure must be upgraded to support the added backhaul backbone infrastructure. Wireless apps are expected to achieve $37 trillion revenue by 2019. This unbelievable growth occurs as the Internet is expanded to implement the interconnection of everything.Digital devices proliferate, machine to machine capabilities vastly expand instrumentation. The digital devices become the engine of a world economy, with apps collecting pennies a day for millions of apps from 8.5 billion people with smart phones by 2019.
Global Electric Resistance Welded Pipes IndustryReportLinker.com
This report analyzes the worldwide markets for Electric Resistance Welded Pipes in Thousand Tons by the following Product Segments: Mechanical Steel Tubing, Structural Tubing, Structural Steel Pipes, Pressure Tubing, Standard Pipes, Oil Country Tubular Goods, and Line Pipes. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East, and Latin America. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets. The report profiles 181 companies including many key and niche players such as Al Jazeera Steel Products Company SAOG, Arabian Pipes Company, ArcelorMittal SA, ERW Pipes Portfolio of ArcelorMittal ChelPipe, Choo Bee Metal Industries Berhad, EVRAZ North America, JFE Steel Corporation, Maharashtra Seamless Limited, Melewar Industrial Group Berhad, Nippon Steel & Sumitomo Metal Corporation, Northwest Pipe Company, OAO TMK, TMK IPSCO, PT Bakrie Pipe Industries, Salzgitter Mannesmann Line Pipe GmbH, Tata Steel Europe, Techint Group SpA, Tenaris S.A., TenarisSiderca, Ternium S.A., United States Steel Corporation, United Metallurgical Company /OMK, Welspun Corp Ltd., Wheatland Tube Company, and Select Products of Wheatland Tube Company. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.
This report analyzes the worldwide markets for Wireless Gaming in US$ Million by the following Product Segments: Messaging Based Wireless Gaming, Browser/Web Based Wireless Gaming, and Downloadable Wireless Gaming. The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. The report profiles 90 companies including many key and niche players such as Blockdot, Inc., DeNA Co., Ltd., Electronic Arts, Inc., Gameloft SA,GAMEVIL, GREE International, Inc., Glu Mobile Inc., GigaMedia Limited, HandyGames, I-play, Itsmy
Hyperalgesia Global Clinical Trials Review, H1, 2013ReportLinker.com
Hyperalgesia Global Clinical Trials Review, H1, 2013
Summary
GlobalData's clinical trial report, 'Hyperalgesia Global Clinical Trials Review, H1, 2013" provides data on the Hyperalgesia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hyperalgesia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Hyperalgesia. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Genital Herpes Global Clinical Trials Review, H1, 2013ReportLinker.com
Genital Herpes Global Clinical Trials Review, H1, 2013
Summary
GlobalData's clinical trial report, 'Genital Herpes Global Clinical Trials Review, H1, 2013" provides data on the Genital Herpes clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Genital Herpes. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Genital Herpes. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
The Future of Direct Communications Technologies and Proximity-based Applicat...ReportLinker.com
Overview: There are a number of technologies that may be deployed that all provide the ability for devices to "discover" one another, although over different distances ranging from centimeters (Near Field Communications), to meters (Bluetooth), to 10s of meters (Wi-Fi). They also all provide the ability for the devices to communicate directly with one another without a centralized network. Some of these use direct communication as their primary mode of communication e.g. NFC or RFID. Others are more traditional networks which provide direct communication ability as an adjunct to their primary network functions e.g. LTE-Direct or Wi-Fi Direct. Most of the short-term drivers for proximity-based services will be mobile advertising and social networking, especially friend-finder services or dating services, and gaming. In the longer term, other applications will come into play within the scope of the so called Internet of Things. The challenge and opportunity for network operators will be to develop new user scenarios and even new business models to generate revenues from these services. This research uncovers opportunities that will be both beneficial and disruptive to the existing ecosystem and value chain. This research is must reading for any company that is considering offerings within proximity and direct communications and any company that wants to stay ahead of the crowd in terms of preparation for these disruptive technologies. Target Audience: ' Mobile network operators' Industry verticals of all types' Wireless device manufacturers' Network infrastructure companies' Advertising agencies, brands, and merchants' Social networks, advertising, and content providers' Proximity, location, and direct communications vendors Key Report Benefits: ' Market forecasts for each significant technology/solution approach' Recognize the upcoming role and importance of LTE Direct compared to other solutions' Analysis of the major vendors focused on proximity and direct communications solutions' Understand the relationship between proximity, direct communications and the Internet of Things' Understand the technical and business-related differences between proximity/presence and location' Identify each of the major technologies/solutions for proximity detection, location determination, and direct communications' Evaluation of the market for major applications including public safety, social networking, advertising, the Internet of Things, and general location services Select Companies in Report: ' 3M Company' Alcatel-Lucent' iSIGN' LG' Nokia' Samsung' Qualcomm' Verizon Wireless
Competing in the European Molecular Diagnostics Market: France, Germany, Ital...ReportLinker.com
This new 970-page comprehensive five-country report from Venture Planning Group is designed to help current suppliers and potential market entrants identify and evaluate the major business opportunities emerging in the European molecular diagnostics market during the next five years. The report explores business and technological trends in major European countries (France, Germany, Italy, Spain, UK); provides 5-year test volume/sales forecasts; estimates shares of leading competitors; compares features of major analyzers; profiles leading market players; and identifies specific product and business opportunities facing instrument and consumable suppliers during the next five years.The $4.5 billion molecular diagnostics market is unquestionably the most rapidly growing segment of the in vitro diagnostics industry. The next five years will witness significant developments in reagent systems and automation, as well as introduction of a wide range of new products that will require innovative marketing approaches. The rate of market penetration into routine clinical laboratories, however, will depend on the introduction of and cost-effective automated systems with amplification methods. In order to successfully capitalize on the opportunities presented by the molecular diagnostics market, many companies are already exploiting new technologies as corporate strategic assets, managed in support of business and marketing strategies. Integrating new technology planning with business and corporate strategies will be one of the most challenging tasks for diagnostics companies during the next five years.
Competing in the European Clinical Chemistry and Immunodiagnostic Markets: Fr...ReportLinker.com
This new 900-page five-country market intelligence and technology assessment report from Venture Planning Group will help current suppliers and potential market entrants identify and evaluate emerging opportunities and develop effective strategic responses. The report explores future trends in major European countries (France, Germany, Italy, Spain, UK); provides estimates of the specimen, test and sales volumes, as well as major suppliers sales and market shares; compares features of leading analyzers; profiles key competitors; and identifies specific product and marketing opportunities emerging during the next five years.The clinical chemistry and immunodiagnostic markets are undergoing significant transformation, caused by convergence of new and more stringent regulations; advances in diagnostic technologies, system engineering, automation, and IT; and intensifying competition. However, this evolving marketplace creates exciting opportunities for a variety of new instruments, reagent systems, and auxiliary products, such as specimen preparation devices, controls, and calibrators.
Bradycardia Global Clinical Trials Review, H1, 2013ReportLinker.com
Bradycardia Global Clinical Trials Review, H1, 2013
Summary
GlobalData's clinical trial report, 'Bradycardia Global Clinical Trials Review, H1, 2013" provides data on the Bradycardia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Bradycardia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Bradycardia. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Acid Indigestion / Heartburn/ Pyrosis Global Clinical Trials Review, H1, 2013
Summary
GlobalData's clinical trial report, 'Acid Indigestion / Heartburn/ Pyrosis Global Clinical Trials Review, H1, 2013" provides data on the Acid Indigestion / Heartburn/ Pyrosis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Acid Indigestion / Heartburn/ Pyrosis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Acid Indigestion / Heartburn/ Pyrosis. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Business Valuation Principles for EntrepreneursBen Wann
This insightful presentation is designed to equip entrepreneurs with the essential knowledge and tools needed to accurately value their businesses. Understanding business valuation is crucial for making informed decisions, whether you're seeking investment, planning to sell, or simply want to gauge your company's worth.
Attending a job Interview for B1 and B2 Englsih learnersErika906060
It is a sample of an interview for a business english class for pre-intermediate and intermediate english students with emphasis on the speking ability.
Falcon stands out as a top-tier P2P Invoice Discounting platform in India, bridging esteemed blue-chip companies and eager investors. Our goal is to transform the investment landscape in India by establishing a comprehensive destination for borrowers and investors with diverse profiles and needs, all while minimizing risk. What sets Falcon apart is the elimination of intermediaries such as commercial banks and depository institutions, allowing investors to enjoy higher yields.
RMD24 | Retail media: hoe zet je dit in als je geen AH of Unilever bent? Heid...BBPMedia1
Grote partijen zijn al een tijdje onderweg met retail media. Ondertussen worden in dit domein ook de kansen zichtbaar voor andere spelers in de markt. Maar met die kansen ontstaan ook vragen: Zelf retail media worden of erop adverteren? In welke fase van de funnel past het en hoe integreer je het in een mediaplan? Wat is nu precies het verschil met marketplaces en Programmatic ads? In dit half uur beslechten we de dilemma's en krijg je antwoorden op wanneer het voor jou tijd is om de volgende stap te zetten.
Unveiling the Secrets How Does Generative AI Work.pdfSam H
At its core, generative artificial intelligence relies on the concept of generative models, which serve as engines that churn out entirely new data resembling their training data. It is like a sculptor who has studied so many forms found in nature and then uses this knowledge to create sculptures from his imagination that have never been seen before anywhere else. If taken to cyberspace, gans work almost the same way.
Personal Brand Statement:
As an Army veteran dedicated to lifelong learning, I bring a disciplined, strategic mindset to my pursuits. I am constantly expanding my knowledge to innovate and lead effectively. My journey is driven by a commitment to excellence, and to make a meaningful impact in the world.
Affordable Stationery Printing Services in Jaipur | Navpack n PrintNavpack & Print
Looking for professional printing services in Jaipur? Navpack n Print offers high-quality and affordable stationery printing for all your business needs. Stand out with custom stationery designs and fast turnaround times. Contact us today for a quote!
The world of search engine optimization (SEO) is buzzing with discussions after Google confirmed that around 2,500 leaked internal documents related to its Search feature are indeed authentic. The revelation has sparked significant concerns within the SEO community. The leaked documents were initially reported by SEO experts Rand Fishkin and Mike King, igniting widespread analysis and discourse. For More Info:- https://news.arihantwebtech.com/search-disrupted-googles-leaked-documents-rock-the-seo-world/
India Orthopedic Devices Market: Unlocking Growth Secrets, Trends and Develop...Kumar Satyam
According to TechSci Research report, “India Orthopedic Devices Market -Industry Size, Share, Trends, Competition Forecast & Opportunities, 2030”, the India Orthopedic Devices Market stood at USD 1,280.54 Million in 2024 and is anticipated to grow with a CAGR of 7.84% in the forecast period, 2026-2030F. The India Orthopedic Devices Market is being driven by several factors. The most prominent ones include an increase in the elderly population, who are more prone to orthopedic conditions such as osteoporosis and arthritis. Moreover, the rise in sports injuries and road accidents are also contributing to the demand for orthopedic devices. Advances in technology and the introduction of innovative implants and prosthetics have further propelled the market growth. Additionally, government initiatives aimed at improving healthcare infrastructure and the increasing prevalence of lifestyle diseases have led to an upward trend in orthopedic surgeries, thereby fueling the market demand for these devices.
Premium MEAN Stack Development Solutions for Modern BusinessesSynapseIndia
Stay ahead of the curve with our premium MEAN Stack Development Solutions. Our expert developers utilize MongoDB, Express.js, AngularJS, and Node.js to create modern and responsive web applications. Trust us for cutting-edge solutions that drive your business growth and success.
Know more: https://www.synapseindia.com/technology/mean-stack-development-company.html
Premium MEAN Stack Development Solutions for Modern Businesses
Epigenomics: Emerging Opportunities in Biomarkers, Diagnostics and Therapeutics
1. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Epigenomics: Emerging Opportunities in Biomarkers, Diagnostics
and Therapeutics
Published on March 2010
Report Summary
THIS REPORT:
Provides a comprehensive overview of the global market for epigenomics
Describes the major epigenomics technologies impacting the market today and emerging opportunities in biomarkers, diagnostics and
therapeutics
Contains global market forecasts for epigenomics, with trends and forecasts for growth through 2014
Offers a focus on particular applications of epigenomics, including research tools, diagnostics, drugs and cloning/tissue engineering
Discusses industry structure including, mergers and acquisitions, distribution of products, government regulation and industry trends
Profiles the most competitive businesses in the industry.
Table of Content
Chapter- 1: INTRODUCTION
STUDY GOALS AND OBJECTIVES 1
REASONS FOR DOING THE STUDY 1
INTENDED AUDIENCE 2
SCOPE OF REPORT 2
METHODOLOGY 2
INFORMATION SOURCES 3
RELATED BCC REPORTS 3
BCC ONLINE SERVICES 3
DISCLAIMER 4
CHAPTER TWO: SUMMARY
SUMMARY 5
SUMMARY TABLE GLOBAL VALUE OF EPIGENOMIC PRODUCTS, BY APPLICATION, THROUGH 2014 ($ MILLIONS) 6
SUMMARY FIGURE GLOBAL VALUE OF EPIGENOMIC PRODUCTS, BY APPLICATION, 2008-2014 ($ MILLIONS) 6
SUMMARY (CONTINUED) 7
CHAPTER THREE: OVERVIEW
INTRODUCTION 8
THE NEW PARADIGM OF EPIGENOMICS 8
FIGURE 1 EPIGENOMICS: A NEW PARADIGM 9
HOW EPIGENOMICS FITS WITHIN GENOMICS 10
Epigenomics: Emerging Opportunities in Biomarkers, Diagnostics and Therapeutics Page 1/15
2. Find Industry reports, Company profiles
ReportLinker and Market Statistics
TABLE 1 GENOMICS PLATFORMS 10
HOW EPIGENOMICS FITS WITHIN ' (CONTINUED) 11
TECHNICAL SCOPE OF THIS REPORT 12
TABLE 2 TECHNOLOGY SCOPE OF THIS REPORT 12
MARKET POTENTIAL OF EPIGENOMICS 13
TABLE 3 GLOBAL VALUE OF EPIGENOMIC PRODUCTS, BY APPLICATION, THROUGH 2014 ($ MILLIONS) 13
EPIGENOMICS PRODUCTS 14
RESEARCH TOOLS AND REAGENTS 14
DIAGNOSTICS 15
DRUGS 15
FIGURE 2 ACTIVE CANCER EPIGENETIC DRUG CLINICAL TRIALS, BY PHASE AND INDICATION, JANUARY 2010 16
GROWTH DRIVING FORCES 17
GROWTH IN LIFE SCIENCE FUNDING 17
CREATION OF EPIGENOMIC MAPS 17
AGING POPULATION IN DEVELOPED COUNTRIES 17
NEED FOR BETTER CANCER THERAPIES 17
GROWTH IN PERSONALIZED MEDICINE 18
WHY EPIGENETIC TECHNOLOGY IS IMPORTANT 18
FIGURE 3 EPIGENETIC PROCESSES CAN GENERATE ABNORMAL CELLS DURING CELL DEVELOPMENT 18
LIFE CYCLE STATUS OF EPIGENOMICS TECHNOLOGIES 19
HISTORICAL BACKGROUND 20
TABLE 4 HISTORICAL OVERVIEW OF EPIGENOMICS 20
HISTORICAL BACKGROUND (CONTINUED) 21
THE EPIGENOMICS INDUSTRY 22
TABLE 5 EPIGENOMICS INDUSTRY KEY COMPANIES 23
THE EPIGENOMICS INDUSTRY (CONTINUED) 24
CHAPTER FOUR: EPIGENETIC TECHNOLOGIES
INTRODUCTION 25
EPIGENETIC ANALYSIS TECHNOLOGIES 25
TABLE 6 EPIGENETIC ANALYSIS TECHNOLOGIES 26
STATUS OF DNA AND HISTONE ANALYSIS TECHNOLOGIES 26
TABLE 7 STATUS OF DNA METHYLATION AND HISTONE ANALYSIS TECHNOLOGIES 26
TABLE 7 (CONTINUED) 27
DNA AND HISTONE ANALYSIS WORKFLOW 28
FIGURE 4 UPSTREAM AND DOWNSTREAM STEPS IN EPIGENETIC ANALYSIS WORKFLOW 29
DNA METHYLATION 29
METHYLATED CYTOSINE'A FIFTH BASE 29
FIGURE 5 EPIGENETIC CHANGES TO DNA AFFECT GENE EXPRESSION 30
BIOLOGICAL ROLE OF DNA METHYLATION 30
TABLE 8 BIOLOGICAL ROLES OF DNA METHYLATION 31
DNA METHYLTRANSFERASE ENZYMES 32
CPG ISLANDS 33
TABLE 9 DESCRIPTION OF CPG ISLANDS 34
HISTONE METHYLATION AND ACETYLATION 35
HISTONES 35
HISTONE MODIFICATIONS 36
FIGURE 6 ACETYLATION OF HISTONE TAIL REGIONS 36
HISTONE ACETYLATION AND METHYLATION ENZYMES 37
Epigenomics: Emerging Opportunities in Biomarkers, Diagnostics and Therapeutics Page 2/15
3. Find Industry reports, Company profiles
ReportLinker and Market Statistics
FIGURE 7 HISTONE ACETYLATION AND METHYLATION ENZYMES 38
Histone Acetyl Transferases (HAT) 38
Histone Deacetylases (HDAC) 39
TABLE 10 HDAC ENZYMES CLASSES 39
Histone Methyltransferases and Demethylases 39
INAPPROPRIATE METHYLATION AND ACETYLATION 40
TABLE 11 MECHANISMS FOR INAPPROPRIATE METHYLATION AND ACETYLATION 40
CHAPTER FIVE: EPIGENOMIC ANALYSIS TECHNOLOGIES
IMPORTANCE OF EPIGENOMIC RESEARCH TOOLS 41
DNA METHYLATION RESEARCH TOOLS 42
TABLE 12 DNA METHYLATION ANALYSIS ASSAYS 42
DNA METHYLATION RESEARCH TOOLS (CONTINUED) 43
TABLE 13 EMERGING DNA METHYLATION TECHNOLOGIES 44
TABLE 14 ACROYNMS FOR DNA METHYLATION TECHNOLOGIES 45
DNA METHYLATION ANALYSIS WORKFLOW 46
FIGURE 8 METHYLATED DNA ANALYSIS WORKFLOW 47
DNA METHYLATION ANALYSIS METHODS BY COVERAGE AND THROUGHPUT 47
TABLE 15 DNA METHYLATION TECHNOLOGIES BY COVERAGE AND THROUGHPUT 48
DNA METHYLATION ANALYSIS TYPES BY WORKFLOW 49
TABLE 16 EXAMPLES OF DNA METHYLATION ASSAYS 49
DNA METHYLATION ANALYSIS: UPSTREAM TECHNOLOGIES 50
TABLE 17 METHYLATION RECOGNITION TECHNOLOGIES 50
RESTRICTION ENZYME-BASED METHODS 51
FIGURE 9 ANALYSIS OF DNA METHYLATION BY RESTRICTION ENZYMES 52
BISULFITE-BASED METHODS 52
Bisulfite-based Methods (Continued) 53
FIGURE 10 BISULFITE CONVERSION OF DNA 54
Analysis of Low Complexity DNA 55
AFFINITY-BASED METHODS 56
CHALLENGE OF HIGH BACKGROUND METHYLATED DNA 57
GENOME WIDE DNA METHYLATION ANALYSIS 57
TABLE 18 DNA METHYLATION ANALYSIS TECHNIQUES BY GENOME RESOLUTION 58
HISTONE EPIGENETIC ANALYSIS TECHNOLOGIES 59
TABLE 19 CHIP ASSAYS 60
CHIP'CHIP AND CHIP-SEQ 61
FIGURE 11 WORKFLOW SCHEMATIC FOR CHIP PLATFORMS 61
TABLE 20 TECHNOLOGIES FOR MAPPING GENOMIC LOCATION OF CHROMATIN PROTEINS AND ENZYMES 62
EMERGING DOWNSTREAM EPIGENETIC ANALYSIS PLATFORMS 63
MICROARRAYS 63
TABLE 21 MICROARRAY TYPES 63
TABLE 22 COMPARISON OF DNA AND PROTEIN MICROARRAY TECHNOLOGIES 64
DNA Microarray Technologies 65
FIGURE 12 MICROARRAY FEATURE DENSITY 66
FIGURE 13 MICROARRAY RESOLUTION 66
TABLE 23 MICROARRAY GENOME CONTENT 67
TABLE 24 DNA MICROARRAY PLATFORM FEATURES 68
TABLE 25 DNA MICROARRAY PLATFORM COMPARISON FOR MAJOR MANUFACTURERS 69
DNA Microarray ' (Continued) 70
Epigenomics: Emerging Opportunities in Biomarkers, Diagnostics and Therapeutics Page 3/15
4. Find Industry reports, Company profiles
ReportLinker and Market Statistics
Microarrays for Epigenetics Analysis 71
FIGURE 14 MICROARRAYS ENHANCE MULTIPLEX CAPABILITIES OF EPIGENETICS ASSAYS 71
Microarrays for ' (Continued) 72
NEXT GENERATION DNA SEQUENCING 73
FIGURE 15 DNA SEQUENCING PLATFORMS 73
Next Generation DNA ' (Continued) 74
Next Generation DNA ' (Continued) 75
FIGURE 16 NEXT GENERATION SEQUENCING TECHNOLOGIES WORKFLOW OVERVIEW 76
SERIAL ANALYSIS OF GENE EXPRESSION 77
ANTIBODIES 78
ALTERNATIVES TO ANTIBODIES IN UPSTREAM ANALYSIS STEP 79
ALTERNATIVES TO ANTIBODIES IN ' (CONTINUED) 80
CHAPTER SIX: EPIGENETICS DIAGNOSTICS TECHNOLOGIES
WHAT IS A BIOMARKER'
TABLE 26 ROLE OF BIOMARKERS IN CLINICAL TRIAL DESIGN
DNA METHYLATION AS A CANCER BIOMARKER
DNA METHYLATION IN CANCER ETIOLOGY
TABLE 27 BIOLOGICAL RATIONALE FOR DNA METHYLATION CANCER BIOMARKERS
TABLE 28 CANCER-RELATED CELL PATHWAYS AND GENES AFFECTED BY HYPER-METHYLATION
Cell Cycle Control
Cell Invasion and Adhesion
DNA Damage Repair
Growth Factor Response
Regulation of Apoptosis
Hormonal Response
Cytokine Signaling
TABLE 29 CANCER-RELATED EPIGENETIC CHANGES
COMPARISON OF MOLECULAR BIOMARKER PLATFORMS
TABLE 30 COMPARISON OF KEY CANCER BIOMARKER TECHNOLOGY PLATFORMS
Comparison of Molecular ' (Continued)
Comparison of Molecular ' (Continued)
ASSESSMENT OF DNA METHYLATION BIOMARKER COMPETITIVE POSITION
EPIGENETIC BIOMARKER GENES
TABLE 31 PUBLISHED DNA METHYLATION BIOMARKER GENES FOR CANCERS
TABLE 32 DIFFERENTIALLY METHYLATED GENES IN NEUROLOGIC AND CARDIOVASCULAR DISORDERS
BIOMARKER DISCOVERY PROCESS
METHYLATION BIOMARKER DISCOVERY TECHNOLOGIES
TABLE 33 DNA METHYLATION ANALYSIS TECHNOLOGIES IN BIOMARKER DISCOVERY
GENOME-WIDE SCANNING FOR BIOMARKER DISCOVERY
CASE STUDY: FROM RESEARCH TOOLS TO BIOMARKERS
IN-VITRO DIAGNOSTIC DEVELOPMENT PROCESS
PHASE 1: BIOMARKER DISCOVERY
PHASE 2: BIOMARKER VALIDATION
PHASE 3: FORMAL KIT DEVELOPMENT
PHASE 4: CLINICAL VALIDATION
PHASE 5: REGULATORY REVIEW AND APPROVAL
FUTURE STATUS OF DNA METHYLATION BIOMARKERS
TABLE 34 TECHNICAL HURDLES FOR DEVELOPMENT OF METHYLATION EPIGENETIC CANCER BIOMARKERS
Epigenomics: Emerging Opportunities in Biomarkers, Diagnostics and Therapeutics Page 4/15
5. Find Industry reports, Company profiles
ReportLinker and Market Statistics
FUTURE STATUS OF DNA ' (CONTINUED)
CHAPTER SEVEN: EPIGENETIC CANCER DRUG TECHNOLOGIES
INTRODUCTION 102
EPIGENETICS IN TUMORIGENESIS 102
EPIGENETIC GENES IN HUMAN CANCER 102
TABLE 35 EPIGENETIC GENES ALTERED IN HUMAN CANCERS 103
TABLE 35 (CONTINUED) 104
EPIGENETIC ENZYME DRUG TARGETS 105
FIGURE 17 HISTONE DEACETYLASE REACTION 105
TABLE 36 STATUS OF INHIBITORS OF EPIGENETIC ENZYMES TARGETING HISTONES 106
HISTONE DEACETYLASE INHIBITORS 107
BENEFITS OF HDAC INHIBITORS 108
HDAC INHIBITOR DRUG CLASSES 109
TABLE 37 HDAC INHIBITOR CLASSES AND RELATIVE POTENCY 109
Hydroxamates 110
FIGURE 18 CHEMICAL STRUCTURE OF TRICHOSTATIN A, A HYDROXAMATE CLASS HDAC INHIBITOR 110
Aliphatic Acids 110
FIGURE 19 PHENYLBUTYRIC ACID, AN ALIPHATIC ACID CLASS HDAC INHIBITOR 111
Cyclic Tetrapeptides 111
FIGURE 20 APICIDIN A, A CYCLIC TETRAPEPTIDE CLASS HDAC INHIBITOR 111
Benzamides 112
FIGURE 21 ENTINOSTAT, A BENZAMIDE CLASS HDAC INHIBITOR 112
HDAC INHIBITOR TECHNOLOGY TRENDS 113
TABLE 38 HDAC INHIBITOR DRUG TECHNOLOGY TRENDS 113
Enzyme Selectivity 113
Enzyme Selectivity (Continued) 114
TABLE 39 HDAC INHIBITOR CLASS I AND II SELECTIVITY 115
Potency 115
Improvements in Drug-like Properties 116
SELECTIVE HDAC COMPOUNDS CAN PROVIDE COMPETITIVE ADVANTAGE 116
FIGURE 22 DISEASE HDAC ISOFORM GENE EXPRESSION PROFILE 117
CHEMICAL DESIGN IS THE KEY TO HDAC INHIBITOR SELECTIVITY 118
FIGURE 23 COMMON STRUCTURAL COMPONENT MOTIFS OF VORINOSTAT 118
Chemical Design ' (Continued) 119
HDAC INHIBITORS IN COMBINATION THERAPIES 120
TABLE 40 DRUG CLASSES THAT CAN BE USED IN COMBINATION WITH HDAC INHIBITORS 121
HDAC INHIBITORS AS THERAPIES OUTSIDE CANCER 122
DERMATOLOGICAL DISORDERS 123
PARASITIC DISEASES 123
NEURODEGENERATIVE DISEASES 124
DIABETES 125
INFLAMMATORY DISEASES 125
IMMUNE DISORDERS 125
DNA METHYLTRANSFERASE INHIBITORS 126
FIGURE 24 LEAD DNMT INHIBITOR COMPOUNDS 126
TECHNICAL CHALLENGES FOR EPIGENETIC DRUG DEVELOPMENT 127
TABLE 41 FUTURE CHALLENGES FOR EPIGENETIC DRUG DEVELOPMENT 127
TECHNICAL CHALLENGES FOR ' (CONTINUED) 128
Epigenomics: Emerging Opportunities in Biomarkers, Diagnostics and Therapeutics Page 5/15
6. Find Industry reports, Company profiles
ReportLinker and Market Statistics
CHAPTER EIGHT: EPIGENETICS CLONING AND CELLULAR
SOMATIC CELL NUCLEAR TRANSFER 129
FIGURE 25 SOMATIC CELL NUCLEAR TRANSFER 129
TABLE 42 TECHNOLOGY OPPORTUNITIES IN SOMATIC CELL NUCLEAR TRANSFER 130
APPLICATIONS 130
REPROGRAMMING FACTORS 131
FIGURE 26 EPIGENETIC PROGRAMMING OF STEM CELLS 132
QUALITY CONTROL ASSAYS IN CELLULAR THERAPIES 132
Tissue Engineering 133
Stem Cell Therapies 133
Non-stem Cell Therapies 134
CHAPTER NINE: LARGE SCALE REGIONAL EPIGENOMICS PROJECTS
LARGE SCALE REGIONAL EPIGENOMICS PROJECTS 135
TABLE 43 REGIONAL EPIGENOMICS INITIATIVES 136
TABLE 43 (CONTINUED) 137
EUROPE 137
UNITED STATES 138
ASIA 139
Asia (Continued) 140
CHAPTER TEN: CANCER DIAGNOSTICS APPLICATIONS
ATTRACTIVE CANCER INDICATIONS FOR SCREENING MARKETS 141
FIGURE 27 CANCER SCREENING OPPORTUNITY MATRIX FOR MOLECULAR DIAGNOSTICS 142
EPIGENETICS AS A SCREENING PLATFORM 143
FIGURE 28 NEW EPIGENETIC SCREENING PARADIGM 144
DIAGNOSTIC SENSITIVITY AND SPECIFICITY 144
FIGURE 29 SENSITIVITY AND SPECIFICITY 145
STATUS OF DIAGNOSTICS TESTS FOR SELECTED CANCER INDICATIONS 146
BLADDER CANCER 146
CARCINOMA OF UNKNOWN PRIMARY (CUP) 147
TABLE 44 COMMERCIAL MOLECULAR DIAGNOSTIC PLATFORMS FOR TISSUE OF ORIGIN TESTS 148
CERVICAL CANCER 149
TABLE 45 COMMERCIAL LANDSCAPE FOR HPV TESTS 150
Cervical Cancer (Continued) 151
COLORECTAL CANCER 152
Colorectal Cancer Existing Screening Tests 152
TABLE 46 CURRENT SCREENING AND DIAGNOSTICS TESTS FOR COLORECTAL CANCER 153
TABLE 47 ACCURACY OF EXISTING COLORECTAL SCREENING TESTS 154
Molecular Colorectal Cancer Diagnostics Tests 155
TABLE 48 COMMERCIAL LANDSCAPE FOR COLORECTAL MOLECULAR TESTS 155
Molecular ' (Continued) 156
TABLE 49 COMPETITIVE SITUATION FOR CONVENTIONAL AND MOLECULAR COLON CANCER SCREENING TESTS 157
Colorectal Cancer Diagnostics Tests 158
GASTRIC CANCER 158
LUNG CANCER 159
Epigenomics: Emerging Opportunities in Biomarkers, Diagnostics and Therapeutics Page 6/15
7. Find Industry reports, Company profiles
ReportLinker and Market Statistics
Lung Cancer (Continued) 160
OVARIAN CANCER 161
TABLE 50 OVARIAN CANCER SCREENING TESTS 161
TABLE 51 OVARIAN CANCER DIAGNOSTIC TEST STATUS 162
PANCREATIC CANCER 163
PEDIATRIC CANCERS 163
PROSTATE CANCER 164
Prostate Cancer (Continued) 165
PERSONALIZED TREATMENT EPIGENETIC-BASED TESTS 166
KEY CLINICAL REQUIREMENTS FOR AN EPIGENETIC-BASED DIAGNOSTICS TEST 166
TABLE 52 REQUIREMENTS FOR AN EPIGENETICS BISULFITE DIAGNOSTIC ASSAY 167
DNA METHYLATION DIAGNOSTICS PIPELINE 168
TABLE 53 EPIGENETIC DIAGNOSTICS DEVELOPMENT PIPELINE 168
TABLE 53 (CONTINUED) 169
DNA METHYLATION DIAGNOSTICS ' (CONTINUED) 170
CHAPTER ELEVEN: THERAPEUTIC APPLICATIONS
EPIGENETIC DRUG CLINICAL TRIALS 171
TABLE 54 APPROVED EPIGENETIC DRUGS 171
TABLE 55 NEXT GENERATION EPIGENETIC DRUGS 171
FIGURE 30 ACTIVE CANCER EPIGENETIC DRUG CLINICAL TRIALS, BY DRUG CLASS AND CANCER TYPE, JANUARY 2010
172
FIGURE 30 (CONTINUED) 173
FIGURE 31 ACTIVE CANCER EPIGENETIC DRUG CLINICAL TRIALS, BY PHASE AND INDICATION, JANUARY 2010 174
FIGURE 32 CURRENT EPIGENETIC CANCER DRUG CLINICAL TRIALS, BY DRUG AND TRIAL TYPE, JANUARY 2010 175
FIGURE 33 ACTIVE EPIGENETIC CANCER DRUG CLINICAL TRIALS, BY CLINICAL PHASE AND TRIAL TYPE, JANUARY 2010
176
EPIGENETIC DRUG NOMENCLATURE 177
TABLE 56 EPIGENETIC DRUG NOMENCLATURE TABLE 177
TABLE 56 (CONTINUED) 178
HDAC INHIBITOR CLINICAL TRIALS 178
TABLE 57 HDAC INHIBITOR CLINICAL TRIALS SUMMARY 178
TABLE 57 (CONTINUED) 179
HDAC INHIBITOR CLINICAL TRIALS (CONTINUED) 179
HDAC INHIBITOR CLINICAL TRIALS (CONTINUED) 180
TABLE 58 MBCD0103 INHIBITS SELECTED HDAC ENZYMES 181
HDAC INHIBITOR CLINICAL TRIALS (CONTINUED) 182
DNMT INHIBITORS CLINICAL TRIALS 183
TABLE 59 DNMT INHIBITOR CLINICAL TRIALS SUMMARY 183
DNMT INHIBITORS CLINICAL TRIALS (CONTINUED) 184
EPIGENETIC DRUGS FOR NON-CANCER INDICATIONS 185
TABLE 60 EPIGENETIC NON-CANCER DRUG LANDSCAPE 186
EPIGENETIC DRUGS FOR NON-CANCER ' (CONTINUED) 187
CHAPTER TWELVE: MARKET GROWTH DRIVING FORCES
EPIGENETICS SCIENTIFIC PUBLICATIONS 188
FIGURE 34 GROWTH IN SCIENTIFIC PUBLICATIONS RELATED TO EPIGENETICS (NUMBER OF PUBLICATIONS) 188
GROWTH DRIVING FORCES 189
Epigenomics: Emerging Opportunities in Biomarkers, Diagnostics and Therapeutics Page 7/15
8. Find Industry reports, Company profiles
ReportLinker and Market Statistics
TABLE 61 FORCES DRIVING EPIGENOMICS INDUSTRY GROWTH 189
GROWTH IN FUNDING FOR LIFE-SCIENCE RESEARCH 189
TABLE 62 STIMULUS FUNDING ALLOCATED TO UNITED STATES SCIENCE SPENDING 190
FIGURE 35 ANNUAL NIH FUNDING BUDGET, 2000-2009 ($ MILIONS) 190
FIGURE 35 (CONTINUED) 191
CREATION OF EPIGENETIC MAPS 191
RANGE OF OCCURRENCE OF EPIGENETIC CHANGES 192
AGING POPULATIONS IN DEVELOPED COUNTRIES 192
NEED FOR BETTER CANCER THERAPIES 193
GROWTH IN PERSONALIZED MEDICINE 193
UNDERSTANDING OF EPIGENETIC PROCESSES BEYOND CANCER 194
CHAPTER THIRTEEN: MARKET ANALYSIS
MARKET SUMMARY 195
TABLE 63 GLOBAL VALUE OF EPIGENOMIC PRODUCTS, BY APPLICATION, THROUGH 2014 ($ MILLIONS) 195
MARKET SUMMARY (CONTINUED) 196
TABLE 64 GLOBAL VALUE OF EPIGENOMIC PRODUCTS, BY GEOGRAPHY, THROUGH 2014 ($ MILLIONS) 197
RESEARCH TOOLS MARKETS 197
GLOBAL SALES BY PRODUCT 197
TABLE 65 GLOBAL VALUE OF EPIGENOMIC ANALYSIS RESEARCH TOOLS, BY PRODUCT TYPE, THROUGH 2014 ($
MILLIONS) 198
Kits 198
Reagents 198
Microarrays and Next Gen Sequencing 198
Microarrays and ' (Continued) 199
EPIGENOMIC KIT SALES BY TECHNOLOGY 200
TABLE 66 GLOBAL VALUE OF EPIGENOMICS RESEARCH TOOLS KITS, BY TECHNOLOGY, THROUGH 2014 ($ MILLION) 200
Epigenomic Kit ' (Continued) 201
TABLE 67 GLOBAL VALUE OF EPIGENOMIC ANALYSIS KITS, BY FORMAT, THROUGH 2014 ($ MILLIONS) 202
DNA METHYLATION ANALYSIS KIT MARKET 202
DNA Methylation ' (Continued) 203
TABLE 68 GLOBAL VALUE OF DNA METHYLATION RESEARCH TOOLS KITS, BY ANALYSIS OBJECTIVE, THROUGH 2014 ($
MILLIONS) 204
TABLE 69 GLOBAL VALUE OF DNA METHYLATION RESEARCH TOOLS KITS, BY TECHNOLOGY, THROUGH 2014 ($
MILLIONS) 205
TABLE 70 GLOBAL VALUE OF DNA METHYLATION SINGLE LOCI RESEARCH TOOLS KITS, BY TECHNOLOGY, THROUGH
2014 ($ MILLIONS) 206
TABLE 71 GLOBAL VALUE OF DNA METHYLATION GENOME-WIDE RESEARCH TOOLS KITS BY TECHNOLOGY, THROUGH
2014 ($ MILLIONS) 207
HISTONE ANALYSIS KIT MARKET 208
TABLE 72 GLOBAL VALUE OF HISTONE ANALYSIS KITS, BY TECHNOLOGY FORMAT, THROUGH 2014 ($ MILLIONS) 208
EPIGENETICS MICROARRAY MARKETS 208
MICROARRAYS AND NEXT GEN SEQUENCING AS DOWNSTREAM TOOLS 209
MICROARRAY MARKET 209
TABLE 73 GLOBAL VALUE OF EPIGENOMIC MICROARRAYS, BY APPLICATION, THROUGH 2014 ($ MILLIONS) 210
RESEARCH TOOLS REAGENTS MARKET 211
TABLE 74 GLOBAL VALUE OF RESEARCH TOOLS EPIGENOMIC REAGENTS, BY TECHNOLOGY, THROUGH 2014 ($
MILLIONS) 211
Epigenomics: Emerging Opportunities in Biomarkers, Diagnostics and Therapeutics Page 8/15
9. Find Industry reports, Company profiles
ReportLinker and Market Statistics
CHAPTER FOURTEEN: EPIGENOMIC DIAGNOSTICS MARKET
OVERVIEW OF CANCER DIAGNOSTICS MARKET 212
TABLE 75 VALUE OF GLOBAL MOLECULAR DIAGNOSTICS PRODUCTS, BY APPLICATION, THROUGH 2014 ($ MILLIONS) 212
CANCER MOLECULAR DIAGNOSTICS GROWTH DRIVERS 213
EPIGENETICS-BASED DIAGNOSTICS MARKETS 213
TABLE 76 PROJECTED CHANGE IN AGE 65-PLUS POPULATION BY REGION (%) 214
Epigenetics-based ' (Continued) 215
TABLE 77 U.S. CANCER INCIDENCE AND ESTIMATED TREATMENT DECISIONS, 2009 216
TABLE 78 GLOBAL VALUE OF EPIGENETIC DIAGNOSTIC ASSAYS, BY APPLICATION, THROUGH 2014 ($ MILLIONS) 217
TABLE 79 GLOBAL VALUE OF EPIGENETIC DIAGNOSTIC ASSAYS, BY CANCER INDICATION, THROUGH 2014 ($ MILLIONS)
218
Epigenetics-based ' (Continued) 219
CHAPTER FIFTEEN: EPIGENETIC DRUGS MARKETS
OVERVIEW 220
CANCER DRUG MARKET GROWTH DRIVING FORCES 220
CANCER DRUG MARKET ' (CONTINUED) 221
CLINICAL PROOF OF PRINCIPLE OF EPIGENETIC DRUGS IS ESTABLISHED 222
EPIGENETIC THERAPIES BEYOND CANCER 223
EPIGENETIC DRUG MARKET SUMMARY 223
TABLE 80 GLOBAL VALUE OF EPIGENETIC DRUGS, BY CANCER INDICATION, THROUGH 2014 ($ MILLIONS) 224
Hematological 224
Hematological (Continued) 225
Solid Tumors 226
Solid Tumors (Continued) 227
Solid Tumors (Continued) 228
EPIGENETIC DRUG MARKET BY DRUG CLASS 229
TABLE 81 GLOBAL VALUE OF EPIGENETIC DRUGS, BY DRUG CLASS, THROUGH 2014 ($ MILLIONS) 229
HDAC INHIBITORS MARKETS 229
Strategic Opportunities in HDAC Inhibitors 230
TABLE 82 SUMMARY OF HDAC INHIBITOR STRATEGIC OPPORTUNITIES FOR CANCER TREATMENT 230
HDAC Inhibitor Drug Market Size by Indication 231
TABLE 83 GLOBAL VALUE OF HDAC INHIBITOR DRUGS, BY INDICATION, THROUGH 2014 ($ MILLIONS) 232
HDAC Inhibitor Market Size by Technology 233
TABLE 84 GLOBAL VALUE OF HDAC INHIBITOR DRUGS, BY TECHNOLOGY, THROUGH 2014 ($ MILLIONS) 233
DNMT INHIBITORS MARKET 234
TABLE 85 GLOBAL VALUE OF DNMT INHIBITOR DRUGS, BY INDICATION, THROUGH 2014 ($ MILLIONS) 235
TABLE 86 GLOBAL VALUE OF DNMT INHIBITOR DRUGS, BY TECHNOLOGY, THROUGH 2014 ($ MILLIONS) 236
HEMATOLOGICAL CANCER EPIGENETIC DRUG MARKET 236
OVERVIEW OF HEMATOLOGICAL CANCERS 236
TABLE 87 OVERVIEW OF MAJOR HEMATOLOGICAL MALIGNANCIES 237
Overview of Hematological Cancers (Continued) 238
TABLE 88 MDS DRUG COMPARISON 239
HEMATOLOGICAL DRUG MARKET BY INDICATION 240
TABLE 89 HEMATOLOGICAL CANCER EPIGENETIC DRUGS, BY INDICATION, THROUGH 2014 ($ MILLIONS) 240
HDAC Hematological Drug Market 241
TABLE 90 HDAC HEMATOLOGICAL CANCER EPIGENETIC DRUGS, BY INDICATION, THROUGH 2014 ($ MILLIONS) 241
HDAC Hematological ' (Continued) 242
Epigenomics: Emerging Opportunities in Biomarkers, Diagnostics and Therapeutics Page 9/15
10. Find Industry reports, Company profiles
ReportLinker and Market Statistics
TABLE 91 COMPARISON OF THE PTCL DRUGS, FOLYTYN AND ISTODAX 243
DNMT Hematological Drug Market 243
TABLE 92 DNMT HEMATOLOGICAL CANCER EPIGENETIC DRUGS, BY INDICATION, THROUGH 2014 ($ MILLIONS) 244
CHAPTER SIXTEEN: CELL THERAPY ASSAYS MARKETS
TABLE 93 EPIGENETIC CELL THERAPIES MARKETS, BY APPLICATION, THROUGH 2014 ($ MILLIONS) 245
CELL THERAPY ASSAYS MARKETS (CONTINUED) 246
CHAPTER SEVENTEEN: GEOGRAPHICAL MARKETS
TABLE 94 EPIGENOMIC RESEARCH TOOLS MARKETS, BY GEOGRAPHY, THROUGH 2014 ($ MILLIONS) 247
TABLE 95 EPIGENOMIC DIAGNOSTICS MARKETS, BY GEOGRAPHY, THROUGH 2014 ($ MILLIONS) 248
TABLE 96 NUMBER OF HOSPITALS AND CLINICS, BY GEOGRAPHICAL REGION 248
TABLE 97 EPIGENOMIC PHARMACEUTICALS MARKETS, BY GEOGRAPHY, THROUGH 2014 ($ MILLIONS) 249
TABLE 98 EPIGENOMIC CELL THERAPIES MARKETS, BY GEOGRAPHY, THROUGH 2014 ($ MILLIONS) 250
CHAPTER EIGHTEEN: COMPETITOR AND INDUSTRY DYNAMICS
RESEARCH TOOLS 251
TABLE 99 SCOPE OF EPIGENOMIC RESEARCH TOOLS SUPPLIERS 252
FIGURE 36 CHIP-GRADE ANTIBODY SUPPLIER MARKET SHARES, 2009 (%) 253
FIGURE 36 (CONTINUED) 254
DIAGNOSTICS 254
SKILL SET FOR BIOTECHNOLOGY DIAGNOSTICS COMPANIES 254
SHIFTING PARADIGM IN DIAGNOSTICS 255
IN-VITRO DIAGNOSTICS COMPETITORS 256
TABLE 100 IN-VITRO DIAGNOSTICS COMPETITORS 256
In-Vitro Diagnostics ' (Continued) 257
TABLE 101 STRATEGIC ALLIANCE STATUS FOR BIOTECHNOLOGY EPIGENETICS DIAGNOSTICS FIRMS 258
TABLE 102 COMPETITIVE LANDSCAPE FOR MOLECULAR DIAGNOSTICS TECHNOLOGIES 259
EPIGENETIC DRUGS INDUSTRY 259
TABLE 103 RELATIVE STRATEGIC POSITION FOR EPIGENOMIC DRUG COMPANIES 260
FIGURE 37 EPIGENOMIC DRUG COMPANY MARKET SHARES, 2009 261
EPIGENOMIC INDUSTRY STRATEGIC ALLIANCES 262
TABLE 104 EPIGENOMICS STATEGIC ALLIANCES: 2007-2010 263
TABLE 104 (CONTINUED) 264
EPIGENOMIC INDUSTRY ' (CONTINUED) 265
EPIGENOMIC INDUSTRY ' (CONTINUED) 266
EPIGENOMICS INDUSTRY ACQUISITIONS 267
TABLE 105 EPIGENOMICS INDUSTRY ACQUISITIONS, 2007'2010 268
EPIGENOMICS INDUSTRY ' (CONTINUED) 269
CHAPTER NINETEEN: PATENTS
EPIGENOMICS PATENT ACTIVITY 270
FIGURE 38 NUMBER OF EPIGENOMICS PATENTS, BY YEAR, 2000-2009 270
FIGURE 39 NUMBER OF EPIGENOMICS PATENTS, BY GEOGRAPHY, 2000'2009 271
FIGURE 39 (CONTINUED) 272
RESEARCH TOOLS AND DIAGNOSTICS PATENT ACTIVITY 272
Epigenomics: Emerging Opportunities in Biomarkers, Diagnostics and Therapeutics Page 10/15
11. Find Industry reports, Company profiles
ReportLinker and Market Statistics
TABLE 106 EPIGENOMICS AG RESEARCH TOOLS PATENT COVERAGE 272
RESEARCH TOOLS AND ' (CONTINUED) 273
FIGURE 40 BIOTECHNOLOGY DIAGNOSTICS PATENTS, BY COMPANY (%) 274
TABLE 107 PATENT STATUS FOR BIOTECHNOLOGY DIAGNOSTICS COMPANIES 275
PHARMACEUTICALS PATENTS ACTIVITY 276
TABLE 108 HDAC INHIBITOR PATENT CLAIMS, 2004'2006 276
TABLE 108 (CONTINUED) 277
FIGURE 41 NUMBER OF EPIGENOMICS DRUG PATENTS, BY TECHNOLOGY CLASS AND GEOGRAPHY 278
PHARMACEUTICALS PATENTS ACTIVITY (CONTINUED) 279
FIGURE 42 NUMBER OF HDAC INHIBITOR PATENTS, BY COMPANY AND GEOGRAPHY 280
FIGURE 43 NUMBER OF DNMT INHIBITOR PATENTS, BY COMPANY AND GEOGRAPHY 281
PATENT CASE STUDIES 282
CHAPTER TWENTY: COMPANY PROFILES
ABBOTT LABORATORIES 283
ABCAM PLC. 284
ACCESS PHARMACEUTICALS 285
ACETYLON PHARMACEUTICALS 286
ACTIVE MOTIF 286
AFFYMETRIX, INC. 287
AFFYMETRIX, INC. (CONTINUED) 288
TABLE 109 AFFYMETRIX STRATEGIC ALLIANCES 289
TABLE 109 (CONTINUED) 290
AGILENT TECHNOLOGIES, INC. 291
ARNO THERAPEUTICS, INC. 292
ARUP LABORATORIES, INC. 293
ASTELLAS PHARMA, INC. 293
BAYER AG 294
BIOFIELD CORP. 295
BIOSERVE BIOTECHNOLOGIES, LTD. 295
BIOVISION 295
CELGENE CORPORATION 296
CELGENE CORPORATION (CONTINUED) 297
CELLARTIS AB 298
CELLCENTRIC LTD. 298
CELLERON THERAPEUTICS LTD. 299
CELLZOME AG 300
CHIPSCREEN BIOSCIENCES LTD. 301
CHROMA THERAPEUTICS LTD. 302
CLAVIS PHARMA ASA 302
TABLE 110 CLAVIS PHARMA DRUG PIPELINE 303
CONSTELLATION PHARMACEUTICALS 304
CRYSTAL GENOMICS, INC. 304
CURIS 305
EISAI CO. LTD. 305
EPIGENOMICS AG 306
EPIGENOMICS AG (CONTINUED) 307
EPIGENTEK 308
EPITHERAPEUTICS 309
Epigenomics: Emerging Opportunities in Biomarkers, Diagnostics and Therapeutics Page 11/15
12. Find Industry reports, Company profiles
ReportLinker and Market Statistics
ELIXIR PHARMACEUTICALS, INC. 309
ENVIVO PHARMACEUTICALS 310
EOS SPA 311
EPIONTIS GMBH 311
EPIZYME, INC. 312
ES CELL INTERNATIONAL PTE LTD 313
EXONHIT THERAPEUTICS SA 313
F. HOFFMANN-LA ROCHE, LTD. 314
GENEXTRA S.P.A 315
GENPATHWAY, INC. 316
GLAXOSMITHKLINE 316
GLAXOSMITHKLINE (CONTINUED) 317
HUYA BIOSCIENCE INTERNATIONAL 318
ILLUMINA, INC. 319
ILLUMINA, INC. (CONTINUED) 320
TABLE 111 ILLUMINA SEQUENCING TECHNOLOGY SPACE 321
IMAGENES GMBH 322
INTERNATIONAL DRUG DISCOVERY INSTITUTE 323
ITALFARMACO SPA 323
JOHNSON & JOHNSON 324
KARUS THERAPEUTICS LTD. 325
LABORATORY CORPORATION OF AMERICA HOLDINGS 326
LES LABORATOIRES SERVIER 327
LIFE TECHNOLOGIES INC. 328
LIFE TECHNOLOGIES INC. (CONTINUED) 329
MERCK KGAA 330
MERCK & CO. INC. 331
METHYLGENE 332
TABLE 112 METHYLGENE HDAC INHIBITOR PRODUCT PIPELINE 333
MILLIPORE 334
NATUREWISE BIOTECH & MEDICALS CORP. 335
NOVARTIS 336
ONCOLYS BIOPHARMA INC. 337
ONCOMETHYLOME SCIENCES S.A. 338
TABLE 113 ONCOMETHYLOME DNA METHYLATION DIAGNOSTICS PIPELINE 339
ONCOMETHYLOME SCIENCES S.A. (CONTINUED) 340
ORCHID CHEMICALS & PHARMACEUTICALS LIMITED 341
ORION GENOMICS 342
TABLE 114 ORION STRATEGIC ALLIANCES 343
TABLE 115 ORION EPIGENETIC DIAGNOSTICS PIPELINE 344
ORTHO BIOTECH 345
PACIFIC BIOSCIENCES 345
PHARMACYCLICS 346
PROGEN PHARMACEUTICALS LTD. 347
PROGEN PHARMACEUTICALS LTD. (CONTINUED) 348
PROGNOSDX HEALTH, INC. 349
QUEST DIAGNOSTICS 349
ROCHE LIFE SCIENCES 350
ROCHE LIFE SCIENCES (CONTINUED) 351
ROCHE LIFE SCIENCES (CONTINUED) 352
Epigenomics: Emerging Opportunities in Biomarkers, Diagnostics and Therapeutics Page 12/15
13. Find Industry reports, Company profiles
ReportLinker and Market Statistics
QIAGEN GMBH 353
RAINDANCE TECHNOLOGIES 354
REACTION BIOLOGY CORP. 354
REPLIGEN CORPORATION 355
RUBICON GENOMICS 355
RUBICON GENOMICS (CONTINUED) 356
S*BIO PTE LTD 357
TABLE 116 S*BIO HDAC INHIBITOR DRUG PIPELINE 358
SCHERING PLOUGH CORPORATION 358
SCOTTISH BIOMEDICAL LTD. 359
SEQUENOM, INC. 360
SEQUENOM, INC. (CONTINUED) 361
SEQWRIGHT 362
SUPERGEN, INC. 362
SYNDAX PHARMACEUTICALS, INC. 363
TABLE 117 ENTINOSTAT CLINICAL TRIALS SUMMARY STATUS 363
SYSMEX CORPORATION 364
TAIHO PHARMACEUTICALS 365
TAKEDA PHARMACEUTICAL COMPANY LIMITED 365
TARGECEPT, INC. 366
THEREPI INC. 366
TOPOTARGET A/S 366
TOPOTARGET A/S (CONTINUED) 367
TOPOTARGET A/S (CONTINUED) 368
TABLE 118 TOPOTARGET'S HDAC INHIBITOR PATENT PORTFOLIO 369
VALIBIO SA 370
VALIRX 371
VERIDEX LLC 371
ZYMO RESEARCH 372
Epigenomics: Emerging Opportunities in Biomarkers, Diagnostics and Therapeutics Page 13/15
14. Find Industry reports, Company profiles
ReportLinker and Market Statistics
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
If you have any questions please visit http://www.reportlinker.com/notify/contact
Order Information
Please verify that the product information is correct and select the format(s) you require.
Epigenomics: Emerging Opportunities in Biomarkers, Diagnostics and Therapeutics
Product Formats
Please select the product formats and the quantity you require.
1 User License--USD 4 850.00 Quantity: _____
Contact Information
Please enter all the information below in BLOCK CAPITALS
Title: Mr Mrs Dr Miss Ms Prof
First Name: _____________________________ Last Name: __________________________________
Email Address: __________________________________________________________________________
Job Title: __________________________________________________________________________
Organization: __________________________________________________________________________
Address: __________________________________________________________________________
City: __________________________________________________________________________
Postal / Zip Code: __________________________________________________________________________
Country: __________________________________________________________________________
Phone Number: __________________________________________________________________________
Fax Number: __________________________________________________________________________
Epigenomics: Emerging Opportunities in Biomarkers, Diagnostics and Therapeutics Page 14/15
15. Find Industry reports, Company profiles
ReportLinker and Market Statistics
Payment Information
Please indicate the payment method, you would like to use by selecting the appropriate box.
Payment by credit card Card Number: ______________________________________________
Expiry Date __________ / _________
CVV Number _____________________
Card Type (ex: Visa, Amex…) _________________________________
Payment by wire transfer Crédit Mutuel
RIB : 10278 07314 00020257701 89
BIC : CMCIFR2A
IBAN : FR76 1027 8073 1400 0202 5770 189
Payment by check UBIQUICK SAS
16 rue Grenette – 69002 LYON, FRANCE
Customer signature:
Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at
http://www.reportlinker.com/index/terms
Please fax this form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
Epigenomics: Emerging Opportunities in Biomarkers, Diagnostics and Therapeutics Page 15/15